Figure 3. Allo-iMSC/CCL19 therapy regressed CT26 tumor growth in vivo (A–C) PBS, syn-iMSC, allo-iMSC, syn-iMSC/CCL19 or allo-iMSC/CCL19 were i.t. injected into CT26-bearing BALB/c mice 10 and 13 days after tumor inoculation. Individual tumor size (A) and mean (B) are shown. The percentage of tumor-free mice is indicated. (C) The mean±SD of tumor size on day 28 are shown. (D) PBS, BALB/c-derived iMSC/CCL19 or C57BL/6-derived iMSC/CCL19 were i.t. injected into CT26-bearing CB6F1 mice 10 and 13 days after tumor inoculation. Individual tumor size and the number of tumor-free mice are shown (left). The mean±SD are shown (right). *p<0.05, **p<0.01 by Tukey (analysis of variance). N.S.: not significant. These experiments were performed twice. CCL19, (C-C motif) ligand 19; iMSC, immortalized mesenchymal stem cell; i.t., intratumoral; PBS, phosphate-buffered saline; syn-iMSC, syngeneic iMSC.